S. 832 119th Congress Senate

EPIC Act of 2025

Official title: A bill to amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

Introduced: March 4, 2025 Introduced by: Thom Tillis Republican · North Carolina See on congress.gov

Health

Everywhere this bill has been 2 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 4, 2025

Read twice and referred to the Committee on Finance.

Mar 4, 2025

Introduced in Senate

Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

What's happening now March 4, 2025

Read twice and referred to the Committee on Finance.

Plain-English summary Congressional Research Service

Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025

This bill lengthens the amount of time for which drug products must have market approval in order for the products to qualify for negotiation under the Medicare Drug Price Negotiation Program.

The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.

The bill modifies these provisions so as to require drug products to also have had at least 11 years of market approval in order to qualify for negotiation beginning in 2028.

Bill text 1 version

Introduced in Senate Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

Committees of jurisdiction 1

Finance Committee
Senate

Lobbying activity 214

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

SANOFI US SERVICES INC.
for SANOFI US SERVICES INC · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
BIOTECHNOLOGY INNOVATION ORGANIZATION
for BIOTECHNOLOGY INNOVATION ORGANIZATION · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
EMD SERONO, INC.
for EMD SERONO INC · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
WILLIAMS AND JENSEN, PLLC
for PHRMA · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
GSK (FKA GLAXOSMITHKLINE INC.)
for GSK (FKA GLAXOSMITHKLINE INC.) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)

Bodies those filers lobbied

HOUSE OF REPRESENTATIVES
211 filings
SENATE
211 filings
Health & Human Services, Dept of (HHS)
89 filings
Centers For Medicare and Medicaid Services (CMS)
85 filings
White House Office
52 filings
U.S. Trade Representative (USTR)
44 filings
Patent & Trademark Office (PTO)
43 filings
Office of Management & Budget (OMB)
39 filings

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

See all 214 filings →

Cosponsors 7